These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

364 related articles for article (PubMed ID: 28671134)

  • 1. Low Cognitive Awareness, but Not Complaint, is a Good Marker of Preclinical Alzheimer's Disease.
    Cacciamani F; Tandetnik C; Gagliardi G; Bertin H; Habert MO; Hampel H; Boukadida L; Révillon M; Epelbaum S; Dubois B;
    J Alzheimers Dis; 2017; 59(2):753-762. PubMed ID: 28671134
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Design and first baseline data of the DZNE multicenter observational study on predementia Alzheimer's disease (DELCODE).
    Jessen F; Spottke A; Boecker H; Brosseron F; Buerger K; Catak C; Fliessbach K; Franke C; Fuentes M; Heneka MT; Janowitz D; Kilimann I; Laske C; Menne F; Nestor P; Peters O; Priller J; Pross V; Ramirez A; Schneider A; Speck O; Spruth EJ; Teipel S; Vukovich R; Westerteicher C; Wiltfang J; Wolfsgruber S; Wagner M; Düzel E
    Alzheimers Res Ther; 2018 Feb; 10(1):15. PubMed ID: 29415768
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Informants' Perception of Subjective Cognitive Decline Helps to Discriminate Preclinical Alzheimer's Disease from Normal Aging.
    Valech N; Mollica MA; Olives J; Tort A; Fortea J; Lleo A; Belén SS; Molinuevo JL; Rami L
    J Alzheimers Dis; 2015 Sep; 48 Suppl 1():S87-98. PubMed ID: 26445275
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evolving Evidence for the Value of Neuroimaging Methods and Biological Markers in Subjects Categorized with Subjective Cognitive Decline.
    Lista S; Molinuevo JL; Cavedo E; Rami L; Amouyel P; Teipel SJ; Garaci F; Toschi N; Habert MO; Blennow K; Zetterberg H; O'Bryant SE; Johnson L; Galluzzi S; Bokde AL; Broich K; Herholz K; Bakardjian H; Dubois B; Jessen F; Carrillo MC; Aisen PS; Hampel H
    J Alzheimers Dis; 2015 Sep; 48 Suppl 1():S171-91. PubMed ID: 26402088
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Executive and Language Subjective Cognitive Decline Complaints Discriminate Preclinical Alzheimer's Disease from Normal Aging.
    Valech N; Tort-Merino A; Coll-Padrós N; Olives J; León M; Rami L; Molinuevo JL
    J Alzheimers Dis; 2018; 61(2):689-703. PubMed ID: 29254090
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cerebrovascular resistance: effects on cognitive decline, cortical atrophy, and progression to dementia.
    Yew B; Nation DA;
    Brain; 2017 Jul; 140(7):1987-2001. PubMed ID: 28575149
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anosognosia Is an Independent Predictor of Conversion From Mild Cognitive Impairment to Alzheimer's Disease and Is Associated With Reduced Brain Metabolism.
    Gerretsen P; Chung JK; Shah P; Plitman E; Iwata Y; Caravaggio F; Nakajima S; Pollock BG; Graff-Guerrero A;
    J Clin Psychiatry; 2017; 78(9):e1187-e1196. PubMed ID: 29022655
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of imaging biomarkers for Alzheimer's disease: amyloid imaging with [18F]florbetapir positron emission tomography and magnetic resonance imaging voxel-based analysis for entorhinal cortex atrophy.
    Tateno A; Sakayori T; Kawashima Y; Higuchi M; Suhara T; Mizumura S; Mintun MA; Skovronsky DM; Honjo K; Ishihara K; Kumita S; Suzuki H; Okubo Y
    Int J Geriatr Psychiatry; 2015 May; 30(5):505-13. PubMed ID: 25043833
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Relationships between flortaucipir PET tau binding and amyloid burden, clinical diagnosis, age and cognition.
    Pontecorvo MJ; Devous MD; Navitsky M; Lu M; Salloway S; Schaerf FW; Jennings D; Arora AK; McGeehan A; Lim NC; Xiong H; Joshi AD; Siderowf A; Mintun MA;
    Brain; 2017 Mar; 140(3):748-763. PubMed ID: 28077397
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Associations Between the Subjective Cognitive Decline-Questionnaire's Scores, Gray Matter Volume, and Amyloid-β Levels.
    Valech N; Sánchez-Benavides G; Tort-Merino A; Coll-Padrós N; Olives J; León M; Falcon C; Molinuevo JL; Rami L
    J Alzheimers Dis; 2019; 72(4):1287-1302. PubMed ID: 31707366
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cross-sectional and longitudinal characterization of SCD patients recruited from the community versus from a memory clinic: subjective cognitive decline, psychoaffective factors, cognitive performances, and atrophy progression over time.
    Kuhn E; Moulinet I; Perrotin A; La Joie R; Landeau B; Tomadesso C; Bejanin A; Sherif S; De La Sayette V; Desgranges B; Vivien D; Poisnel G; Chételat G
    Alzheimers Res Ther; 2019 Jul; 11(1):61. PubMed ID: 31286994
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tau levels are higher in objective subtle cognitive decline but not subjective memory complaint.
    Thomas KR; Weigand AJ; Edwards LC; Edmonds EC; Bangen KJ; Ortiz G; Walker KS; Bondi MW;
    Alzheimers Res Ther; 2022 Aug; 14(1):114. PubMed ID: 35996158
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Florbetapir positron emission tomography and cerebrospinal fluid biomarkers.
    Hake A; Trzepacz PT; Wang S; Yu P; Case M; Hochstetler H; Witte MM; Degenhardt EK; Dean RA;
    Alzheimers Dement; 2015 Aug; 11(8):986-93. PubMed ID: 25916563
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Self- and informant-reported cognitive functioning and awareness in subjective cognitive decline, mild cognitive impairment, and very mild Alzheimer disease.
    Ryu SY; Kim A; Kim S; Park KW; Park KH; Youn YC; Lee DW; Lee JY; Lee JH; Jeong JH; Choi SH; Han HJ; Kim S; Na S; Park M; Yim HW; Yang DW
    Int J Geriatr Psychiatry; 2020 Jan; 35(1):91-98. PubMed ID: 31650618
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Subjective cognitive decline in cognitively normal elders from the community or from a memory clinic: Differential affective and imaging correlates.
    Perrotin A; La Joie R; de La Sayette V; Barré L; Mézenge F; Mutlu J; Guilloteau D; Egret S; Eustache F; Chételat G
    Alzheimers Dement; 2017 May; 13(5):550-560. PubMed ID: 27693187
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Cerebrospinal Fluid Aβ1-42/Aβ1-40 Ratio Improves Concordance with Amyloid-PET for Diagnosing Alzheimer's Disease in a Clinical Setting.
    Niemantsverdriet E; Ottoy J; Somers C; De Roeck E; Struyfs H; Soetewey F; Verhaeghe J; Van den Bossche T; Van Mossevelde S; Goeman J; De Deyn PP; Mariën P; Versijpt J; Sleegers K; Van Broeckhoven C; Wyffels L; Albert A; Ceyssens S; Stroobants S; Staelens S; Bjerke M; Engelborghs S
    J Alzheimers Dis; 2017; 60(2):561-576. PubMed ID: 28869470
    [TBL] [Abstract][Full Text] [Related]  

  • 17. EEG evidence of compensatory mechanisms in preclinical Alzheimer's disease.
    Gaubert S; Raimondo F; Houot M; Corsi MC; Naccache L; Diego Sitt J; Hermann B; Oudiette D; Gagliardi G; Habert MO; Dubois B; De Vico Fallani F; Bakardjian H; Epelbaum S;
    Brain; 2019 Jul; 142(7):2096-2112. PubMed ID: 31211359
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Activities of Daily Living and Depressive Symptoms in Patients with Subjective Cognitive Decline, Mild Cognitive Impairment, and Alzheimer's Disease.
    Stogmann E; Moser D; Klug S; Gleiss A; Auff E; Dal-Bianco P; Pusswald G; Lehrner J
    J Alzheimers Dis; 2016; 49(4):1043-50. PubMed ID: 26577522
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hypertension is associated with worse cognitive function and hippocampal hypometabolism in Alzheimer's disease.
    Moonga I; Niccolini F; Wilson H; Pagano G; Politis M;
    Eur J Neurol; 2017 Sep; 24(9):1173-1182. PubMed ID: 28752644
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Subjective Cognitive Decline in Preclinical Alzheimer's Disease.
    Rabin LA; Smart CM; Amariglio RE
    Annu Rev Clin Psychol; 2017 May; 13():369-396. PubMed ID: 28482688
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.